Essential Heart Failure Drugs Remain Underused in the UK

TOPLINE: Despite an increase in prescription rates of mineralocorticoid receptor antagonists (MRAs) for patients with heart failure with reduced ejection fraction (HFrEF) in the United Kingdom from 2014 to 2019, half of the eligible patients did not receive the therapy. Older age, sex, and the presence of comorbidities were linked to lower prescription rates of …